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Abstract 
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 Tumor necrosis factor (TNF) superfamily has a variety of members which 
have own physiological roles in many types of mammalian cells. Considerable 
research on TNF has revealed that it has many physiological functions in many 
types of cells in addition to induction of cell death, and it induces two distinct 
signaling pathways, NFB activation and cell death via caspase activation. 
However, the relationship of TNF superfamily in mechanisms for the 
determination of the cell death, and their pathophysiological roles for 
non-inflammatory diseases had remained unknown.  
To elucidate the effect of TNF superfamily on cell death, I examined 
apoptotic activity of TNF, homologous to lymphotoxins, shows inducible 
expression, and competes with herpes simplex virus glycoprotein D for HVEM, a 
receptor expressed by T lymphocytes (LIGHT), tumor necrosis factor-related 
apoptosis-inducing ligand (TRAIL) and anti-Fas antibodies (Fas), on behalf of 
Fas ligands, in actinomycin D (ActD)-sensitized hepatocytes. LIGHT does not 
induce apoptosis in human primary hepatocytes even in the presence of ActD, 
whereas the other TNF family ligands induce apoptosis in hepatocytes pretreated 
with ActD. Moreover, LIGHT effectively suppressed the apoptosis mediated by 
ActD/TNF but neither ActD/Fas nor ActD/TRAIL, via NFB activation; thus, 
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suggesting that some TNF superfamily ligands can negatively regulate 
TNF-mediated apoptosis. 
To elucidate the involvement of TNF in non-inflammatory diseases, 
ICAM-1 expression, which is expected to serve as a surrogate marker for TNF 
expression, was examined in Wistar fatty rats (model of diabetic nephropathy). 
The expression increased in the glomeruli of kidney during the progression of the 
nephropathy; thus, suggesting that the pro-inflammatory cytokine TNF has the 
potential to play pathophysiological roles in non-inflammatory diseases such as 
diabetic nephropathy. These results obtained from my studies indicate a part of a 
wide variety of physiological implications for TNF superfamily. 
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ActD  actinomycin D 
Fas  anti-Fas antibody 
BSA bovine serum albumin 
FACS fluorescence-activated cell sorting 
FasL Fas ligand 
FITC fuorescein isothiocyanate 
GalN D-galactosamine 
HVEM herpesvirus entry mediator 
ICAM-1 intercellular adhesion molecule-1 
IFN interferon   
IL-1 interleukin-1 
LARC  liver activation regulated chemokine 
LDH lactate dehydrogenase 
LFA-1 lymphocyte function-associated antigen-1 
LIGHT homologous to lymphotoxins, shows inducible expression, and 
competes with herpes simplex virus glycoprotein D for HVEM, a 
receptor expressed by T lymphocytes 
LT lymphotoxin 
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LTR  lymphotoxin  receptor 
mAb monoclonal antibody 
NCS newborn calf serum 
NFB nuclear factor-B 
PAM periodic acid-methenamine-silver 
PAS periodic acid-schiff 
PBS phosphate buffered saline 
RANTES     regulated on activation normal T cell expressed and secreted 
TNF  tumor necrosis factor 
TNFR TNF receptor 
TRAF TNF receptor-associated factor 
TRAIL tumor necrosis factor-related apoptosis-inducing ligand 
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General Introduction 
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Tumor necrosis factor  (TNF), which is known as a pro-inflammatory 
cytokine, has many types of physiological functions, in addition to its role in the 
induction of inflammatory reactions and apoptosis in some types of tumor cells 
(Eigler et al., 1997). TNF and its receptor each belong to a superfamily composed 
of 19 and 25 members, respectively, based on sequence homology to TNF and the 
receptor (Wallach et al., 2002; Aggarwal et al., 2012).  
One of the main features of the TNF receptor family is the existence of a 
death domain (DD) that plays an important role in the induction of apoptosis. 
TNF receptor TNFRp55 possesses a DD, whereas some of the other receptors lack 
the DD (Hehlgans et al., 2002; Fig. 1A). Studies have identified two distinct 
signaling pathways that are stimulated through typical TNF receptors bound to 
TNF; one is a caspase pathway triggered by caspase-8 activation via interaction 
with DD, TRADD, FADD and the caspase, another is an NFB activation pathway 
mediated by TNF receptor-associated factors (TRAFs), which are coupled to many 
types of TNF receptors. Caspase activation is an especially important event for 
TNF-mediated apoptosis. Moreover, substantial research had been conducted to 
thoroughly understand TNF signaling before my study. However, the 
relationship of TNF superfamily in the pathway through TNF signals apoptosis 
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remained unknown. For instance, several types of cells are resistant to 
TNF-induced apoptosis even though TNFRp55 is expressed in cells where 
caspase activation is expected to be induced. One of reasons for the resistance 
could be based on NFB activation simultaneously induced by TNF. In addition, 
the complexity of TNFsignaling led me to develop an interest in physiological 
significance of TNF and the onset of diseases. I performed two studies to 
elucidate not only the implication of TNF superfamily in TNF receptor signaling 
through the apoptosis and its physiological implications, but also other 
physiological functions in addition to apoptosis and inflammatory reactions.  
Simultaneous activation of NFB and apoptosis by the TNF pathway 
was thought to be the mechanism by which TNFfailed to induce apoptosis in 
several normal cells. As already described, some TNF receptor superfamily 
members lack the DD, which is essential for TNF-mediated apoptosis; however, 
they retain the ability to activate NFB. Thus, treating cells with ligands to these 
receptors leads only to the activation of NFB and not the induction of apoptosis. 
Among categorized receptors, lymphotoxin  receptor (LTR) and the herpesvirus 
entry mediator (HVEM) are reported to interact with a member of the TNF family. 
This ligand, known as LIGHT, is homologous to the lymphotoxins shows inducible 
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expression and competes with herpes simplex virus glycoprotein D for HVEM a 
receptor expressed by T lymphocytes. LIGHT is expected to cause the activation of 
NFB but not caspase processing in treated cells. These previous findings raised 
the hypothesis that LIGHT may suppress TNF-dependent apoptosis via NFB 
activation (Fig. 1B).  
In part 1, I investigated this hypothesis by establishing an actinomycin D 
(ActD)- and TNF-mediated apoptosis assay system using human normal 
hepatocytes and then evaluated the effect of LIGHT on apoptosis. Pro-apoptotic 
ligands like TNF and antibodies for Fas antigens, which bind receptors bearing 
DD, effectively induced apoptosis in ActD-treated cells, whereas LIGHT failed to 
cause apoptosis in these cells. Surprisingly, pretreatment with LIGHT rescued 
ActD- and TNF-treated cells from apoptosis, although the treatment could not 
prevent apoptosis induced by anti-Fas antibodies and TRAIL.  
The complexity of TNF signaling, described in part 1, may enable TNF 
to play a role in a wide variety of physiological functions and non-inflammatory 
diseases. To address the effect of TNFon non-inflammatory diseases, 
sophisticated systems for the detection of TNF gene expression in tissues as well 
as plasma samples were required. At the time when I tried to conduct my study, it 
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was difficult to easily detect cytokines such as TNF in specific tissues. Only 
northern blotting, which detects transcripts of target genes was available for use 
in the targeting of specific tissues. It was easier to detect these molecules in liquid 
samples such as plasma and urine. Therefore, I needed a breakthrough idea to 
tackle this issue. 
 It was reported that TNF induces the expression of adhesion molecules 
on endothelial cells (Mulligan et al., 1993), which causes migration of white blood 
cells into the cytokine-injected tissues (Munro et al., 1989). This suggests that 
adhesion molecules play important roles in the infiltration of inflammatory cells 
into regions of inflammation and their accumulation in these regions. I finally 
came up with an idea that ICAM-1 expression on cells of reporter tissues could 
serve as a surrogate marker for TNF expression in targeted tissues. In parallel 
with insight, it was reported that TNF induced the expression of ICAM-1 in the 
mesangial cells of kidney (Brennan et al., 1990; Sterzel et al., 1993).  
In part 2, to elucidate the implications of TNF and ICAM-1 in the 
nephropathy resulting from non-insulin dependent diabetes mellitus, which was 
thought to be categorized as a non-inflammatory disease, ICAM-1 expression was 
examined in the kidneys of a new genetically obese-hyperglycemic rat (Wistar 
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Fatty), a model that reflects the pathological characteristics of 
non-insulin-dependent diabetic nephropathy. Immunohistochemical analysis 
using anti-ICAM-1 antibodies revealed that ICAM-1 expression increased in the 
glomeruli of Wistar fatty rats during the progression of nephropathy, although no 
infiltration of immune cells was observed. To evaluate whether ICAM-1 caused 
the nephropathy in Wistar fatty rats, the effect of blocking ICAM-1 by chronic 
administration of anti-ICAM-1 antibodies on the urinary excretion of albumin by 
Wistar fatty rats was examined. However, the treatment failed to reduce the 
urinary excretion of albumin. These findings suggest that ICAM-1 expression 
could be a surrogate marker for an increase in TNF expression in the kidney 
during diabetic nephropathy, although ICAM-1 is unlikely to act as a causal factor 
for the pathogenesis of Wistar fatty. 
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A Figure 
 
Figure 1. Conceptual diagram. 
A, Relationship between TNF ligands and their receptors applied in my studies 
Schematic illustration showed the known interactions between members of TNF 
ligand family and members of TNF receptor family, and adaptor proteins and 
signaling pathways associated with those receptors, identified before my studies. 
  
B, My hypothesis about TNF-related signaling on anti-apoptosis 
NFB activation by TNF receptor family was assumed to suppress 
TNF-mediated caspase activation. To investigate the effects of NFB activation 
on caspase activation, LIGHT mediated NFB activation was expected to inhibit 
the apoptosis under the condition that TNF signaling stimulates only caspase 
pathway in the presence of ActD. 
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Part 1 
LIGHT, a Member of the Tumor Necrosis Factor Ligand Superfamily, Prevents 
Tumor Necrosis Factor -mediated Human Primary Hepatocyte Apoptosis, but 
Not Fas-mediated Apoptosis 
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Abstract 
 
 
LIGHT is a member of tumor necrosis factor (TNF) superfamily. Its 
receptors have been identified as lymphotoxin  receptor (LTR) and the 
herpesvirus entry mediator (HVEM)/ATAR/TR2, both of which lack the 
cytoplasmic sequence termed the “death domain.” The present study has 
demonstrated that LIGHT inhibits TNF-mediated apoptosis of human primary 
hepatocytes sensitized by actinomycin D (ActD)-, but not Fas- or TRAIL-mediated 
apoptosis. This protective effect requires LIGHT pretreatment at least 3 h prior to 
ActD sensitization. LIGHT stimulates nuclear factor-B (NFB)-dependent 
transcriptional activity in human hepatocytes such as TNF. The time course of 
NFB activation after LIGHT administration is similar to that of the 
pretreatment required for the anti-apoptotic effect of LIGHT. LIGHT inhibits 
caspase-3 processing during the apoptotic protease cascade in TNF-mediated 
apoptosis but not Fas-mediated apoptosis. These results indicate that LIGHT may 
act as an anti-apoptotic agent against TNF-mediated liver injury by blocking the 
activation of caspase-3. 
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Introduction 
 
 
Members of the TNF ligand superfamily play multiple roles in the 
development of the immune system and in osteogenesis. They also mediate the 
effective function of the innate and adaptive immune responses (Smith et al., 
1994). These proteins include TNF, lymphotoxin  (LT), lymphotoxin  (LT), 
Fas ligand (FasL), CD27L, CD30L, CD40L, 4-1BB (Gruss et al., 1995), TRAIL 
(Wiley et al., 1995), RANKL/OPGL (Anderson et al., 1997; Lacey et al., 1998; 
Wong et al., 1997; Yasuda et al., 1998), TWEAK (Chicheportiche et al., 1997), 
APRIL/TALL-2 (Hahne et al., 1998; Shu et al., 1999), AITRL (Kwon et al., 1999), 
VEG1 (Zhai et al., 1999), and BAFF/TALL-1 (Shu et al., 1999; Schneider et al., 
1999). Recently, LIGHT, which is homologous to the lymphotoxins, shows 
inducible expression, and competes with herpes simplex virus glycoprotein D for 
HVEM. HVEM is a receptor expressed by T lymphocytes that has been identified 
as a member of the TNF ligand superfamily and shown to be about 30% identical 
to FasL and LT  (Mauri et al., 1998). Further studies have revealed that LIGHT 
can bind to lymphotoxin  receptor (LTR) and to herpesvirus entry mediator 
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(HVEM)/ATAR/TR2 (Mauri et al., 1998; Montgomery et al., 1996; Kwon et al., 
1997; Marsters et al., 1997; Hsu et al., 1997). TNF, LT, LT, and LIGHT exhibit 
distinct and overlapping patterns in the binding of four cognate receptors. TNF 
and the homotrimer of LT bind two receptors, TNFRp55 and TNFRp75 (Smith et 
al., 1994); and LT forms heterotrimers with LT, which can bind LTR. The 
complexity of receptor/ligand engagement suggests a functional redundancy of 
these cytokines. However, disruptions of these genes in mice indicate that the 
TNF and LT systems play important roles in the development of the immune 
system (Matsumoto et al., 1996; Neumann et al., 1997; Fu et al., 1997; Koni et al., 
1997; Alimzhanov et al., 1997; Futterer et al., 1998). Moreover, these systems are 
involved more directly in several immune responses. TNF induces cell death in 
many types of cells, and stimulates expression of several chemokines. LTR 
signaling stimulates secretion of chemokines such as interleukin-8, and causes 
cell death in some types of cells under certain culture conditions, such as colon 
adenocarcinoma HT-29 cells (Degli-Esposti et al., 1997; Browning et al., 1996). 
Members of the TNF receptor family like LTR and HVEM are associated with 
TNF receptor associated factors (TRAFs), which bind to the cytoplasmic domains 
of the TNF receptor family. LTR binds TRAF2, TRAF3, and TRAF5, whereas 
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HVEM binds TRAF2 and TRAF5. TRAF2 and TRAF5, but not TRAF3, stimulate 
the activation of several transcriptional regulators, including NFB (Marsters et 
al., 1997; Hsu et al., 1997; Nakano et al., 1996; Mackay et al., 1996; VanArsdale et 
al., 1997), although it is reported that splice variants of TRAF3 are capable of 
inducing NFB activation (van Eyndhoven et al., 1999).  
Because LIGHT engages LTR and HVEM as the cellular receptors, it is 
expected to have physiological functions similar to those of LT and LT. As 
previous studies have shown, LIGHT and LT induce cell death in HT-29 cells 
(Harrop et al., 1998; Zhai et al., 1998; Rooney et al., 2000). LIGHT also causes 
growth arrest in RD cells following the developmental changes to smooth muscles 
cells. Furthermore, LIGHT stimulates cellular secretion of interleukin-8 and 
RANTES (regulated on activation normal T cell expressed and secreted) (Hikichi 
et al., 2001). It has also been reported that LIGHT is one of the CD28-independent 
costimulatory molecules in T cells (Tamada et al., 2000). Recent studies of 
transgenic mice expressing recombinant LIGHT and of mice administered soluble 
HVEM proteins to block LIGHT activity have revealed that LIGHT is required for 
the expansion of T cells, and it plays an important role in T cell homeostasis 
(Wang et al., 2001; Shaikh et al., 2001).  
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TNF plays an important role in the proliferation of hepatocytes in vitro 
and in vivo (Watanabe et al., 1997; Kirillova et al., 1999; Yamada et al., 1997; 
Webber et al., 1998) and acts as a mediator of cell death in several liver injury 
models (Iimuro et al., 1997; Pfeffer et al., 1993; Leist et al., 1995; Gantner et al., 
1995). Hepatocytes are normally resistant to TNF-mediated cytotoxicity. They 
require sensitization with transcription inhibitors such as ActD for maximal 
TNF cytotoxicity (Leist et al., 1994). This suggests that TNFRp55, an essential 
receptor for TNF signaling, stimulates two distinct pathways: one signal 
mediated by NFB that maintains the survival of cells, and another with 
activation of a series of effectors involving the caspase family that results in cell 
death. Recent studies have indicated that the survival signal(s) seems to play a 
dominant role against the death signal(s). Because LIGHT stimulates activation 
of NFB in nonhepatic cells (Hikichi et al., 2001), it is expected to be an 
anti-apoptotic mediator.  
In the present study, I investigated the effects of LIGHT on human 
primary hepatocytes and demonstrated that LIGHT blocks ActD/TNF-induced 
hepatocyte apoptosis, but it does not suppress ActD/agonistic anti-Fas antigen 
monoclonal antibody (Fas)- or ActD/TRAIL-mediated apoptosis. In addition, I 
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propose that LIGHT stimulates NFB transcriptional activity in the human 
primary hepatocytes and inhibits the apoptotic caspase cascade induced by TNF. 
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Materials and Methods 
 
 
Cells and reagents 
Human primary hepatocytes were purchased from Cell Systems (Kirkland, 
USA). The cells were cultured in a basal medium composed of Ham’s F-12 and 
Leivobitz L-15 (1:1) medium (Invitrogen, Carlsbad, USA), 0.2% (v/v) bovine serum 
albumin (Invitrogen), 5 mM glucose (Wako Pure Chemical Inc., Osaka, Japan), 10 
nM dexamethasone (Wako), and 10 nM bovine insulin (Invitrogen) supplemented 
with 10% (v/v) fetal calf serum (JRH, Lenexa, USA). The cells had been expanded 
10-fold, and were stored at －160°C before use. The soluble form of human 
LIGHT protein was produced as previously described (Hikichi et al., 2001). 
Recombinant human TNF, LT, and TRAIL proteins and anti-LTR polyclonal 
antibody (AF629) were purchased from R&D System (Minneapolis, USA). 
Agonistic monoclonal antibody (mAb) against Fas antigen (Fas; CH-11) was 
purchased from MBL (Nagoya, Japan). Anti-TNFRp55 mAb (utr9) and 
anti-TNFRp75 mAb (utr1) were purchased from BMA (Augst, Switzerland). 
Anti-HVEM mAb was kindly provided by Dr. Truneh (Harrop et al., 1998). Rabbit 
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antiserum raised against caspase-3 and FITC conjugated anti-mouse IgG mAb 
were purchased from Pharmingen (San Diego, USA). Rabbit FITC-conjugated 
anti-goat IgG polyclonal antibody was purchased from Vector Laboratories, Inc. 
(Burlingame, USA). Goat antiserum against actin (I-19), goat horseradish 
peroxidase-conjugated anti-rabbit Ig, and donkey horseradish 
peroxidase-conjugated anti-goat Ig were purchased from Santa Cruz 
Biotechnology (Santa Cruz, USA). ActD was purchased from Wako. Several 
protease inhibitors were purchased from Roche Molecular Biochemicals 
(Mannheim, Germany). 
 
Cytotoxicity assay 
Hepatocytes were plated onto 96-well type I collagen-coated plates in a 
basal medium containing 1% newborn calf serum (NCS). They were then 
incubated with 333 nM ActD for 30 min, followed by the addition of various 
amounts of TNF, LT, LIGHT, TRAIL, or Fas for 18 h. The lactate 
dehydrogenase (LDH) activity in the culture supernatants was determined using 
the Cytotoxicity Test-WAKO (Wako). Briefly, culture supernatants were treated 
with the substrate solution for 45 min, and their absorbance at 620 nm was 
25 
 
measured with a plate reader according to the manufacturer’s instructions. To 
examine its anti-apoptotic effect, LIGHT was added to the hepatocyte cultures for 
the indicated times before administration of ActD. Data were expressed as the 
mean ± S.E. for three samples. 
 
Determination of apoptosis by flow cytometry 
Hepatocytes were plated onto 6-well type I collagen-coated plates. They 
were then cultured for 18 h in a basal medium containing 10% NCS. After the 
medium was changed to the basal medium containing 1% NCS, the cells were 
treated with 333 nM ActD for 30 min, followed by the addition of 100 ng/ml TNF, 
LT, LIGHT, or Fas. Apoptosis was determined using the Early Apoptosis 
Detection Kit (Kamiya Biochemical, Seattle, USA). Briefly, 14 h after each 
cytokine addition, the cells were trypsinized, washed with the basal medium, and 
pelleted by centrifugation. After being resuspended, the cells were stained in a 
suspension buffer containing annexin-V or propidium iodide for 20 min. They 
were then analyzed on FACScan using the CELLQuest program (Becton 
Dickinson, San Jose, USA) at an excitation of 488 nm.  
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Reverse transcriptase-PCR analysis 
Hepatocytes cultured in type I collagen-coated 75-cm2 flasks were lysed 
with 0.6 ml of ISOGEN (NipponGene, Japan) by mixing vigorously. The lysates 
were then mixed with CHCl3 and centrifuged. The aqueous phases were collected, 
and RNA precipitation was performed with isopropyl alcohol. Precipitated RNA 
was then resuspended, treated with DNase I (Gene Hunter, Nashville, USA), and 
extracted using the RNeasy Kit (Qiagen, Chatsworth, USA). Reverse 
transcription was performed using the TaqMan reverse transcription reagent kit 
(PE Biosystems, Foster City, USA). A pair of primers 
(5-CCTTACACATACACACCCTTTGGAAGT-3 as a forward primer, and 
5-AGCTCAATGCATGTACAGAATCCCCGGTTA-3 as a reverse primer) were 
designed to amplify the fragments of the CYP3A4 gene. The primers of the LTR 
and HVEM genes were described previously (Hikichi et al., 2001). PCR was 
performed using the Advantage GC-cDNA polymerase mix (Clontech, Palo Alto, 
USA). As a control, PCR was performed using RNA without a reverse 
transcription process. 
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Western blot analysis for caspase-3 processing 
Hepatocytes were plated onto type I collagen-coated 225-cm2 flasks. They 
were treated with or without LIGHT (100 ng/ml) for 6 h in the basal medium 
containing 1% NCS, followed by the induction of apoptosis as described above. The 
cells were harvested with a cell scraper 4 or 14 h after the induction, and stored at 
－80°C until protein extraction. The pellets were resuspended with a lysis buffer 
(50 mM Tris-HCl, pH 8.0, 1 mM EDTA, 150 mM NaCl, 1% Nonidet P-40, 100 M 
4-amidinophenylmethanesulfonyl fluoride, 1 g/ml aprotinin, 5 g/ml leupeptin, 1 
g/ml pepstatin A, and 50 g/ml antipain), and then mixed well at 4°C. After 
centrifugation, the protein concentration of each supernatant was determined 
using the Bio-Rad Protein Assay (Bio-Rad). Samples were subjected to 10-20% 
SDS-PAGE, and subsequently transferred to polyvinylidene difluoride 
membranes (Millipore, Bedford, USA) in a transfer buffer (39 mM glycine, 48 mM 
Tris, 0.037% SDS, and 15% methanol). These membranes were blocked in 
BlockAce (Dainippon Seiyaku, Japan) overnight at 4°C. Rabbit anti-caspase-3 
antibody was used as primary antibody at a 1:1000 dilution in 10% BlockAce for 
30 min. They were then washed in phosphate-buffered saline containing 0.05% 
Tween 20 (Bio-Rad). Goat anti-rabbit Ig antibody was used as secondary antibody 
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at a 1:5000 dilution for 30 min. Chemiluminescence (Amersham Biosciences) was 
then used to visualize immunoreactive protein complexes. The exposure times for 
the detection of procaspase-3 and its processed forms were 1 and 5 min, 
respectively.  
 
NFB transcription assay by a reporter gene system 
Hepatocytes were plated onto 24-well type I collagen-coated plates. They 
were then cultured in the basal medium containing 10% FCS overnight. NFB 
transcriptional activity was determined using the Mercury Pathway Profiling 
SEAP system (Clontech). Briefly, hepatocytes were transfected with 0.5 g of 
pNFB-SEAP vector, pTAL-SEAP vector as a negative control, or pSEAP2-control 
vector as a positive control, using FuGENE6 reagent (Roche Molecular 
Biochemicals). After they were cultured for 1 day, the media were changed to the 
basal medium containing 1% NCS, with or without 100 ng/ml LIGHT, TNF, or 
Fas, respectively. SEAP activity was determined using the Great EscAPe 
chemiluminescence detection kit (Clontech) according to the manufacturer’s 
instructions. The data were expressed as the mean ± S.E. for four samples. 
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Flow cytometry 
The hepatocytes were harvested and stained with anti-HVEM or 
anti-LTR, in phosphate-buffered saline containing 1% FCS and 0.05% NaN3 for 
30 min on ice. The cells were then washed with the above buffer, and the cells 
were exposed to FITC-conjugated anti-mouse Ig antibodies, and analyzed in a 
FACSvantage (BD Biosciences, Mountain View, USA). Cells treated solely with 
secondary antibodies were used as an unstained negative control. 
30 
 
Results 
 
 
Characterization of human primary hepatocytes 
Primary hepatocytes are known to lose several of their physiological 
functions during in vitro cultivation. Consequently, the expression of CYP3A4, a 
hepatocyte marker belonging to the cytochrome P-450 family, was determined by 
reverse transcriptase-PCR in human primary hepatocytes in this experiment. As 
shown in Fig. 2A, the specific PCR product of the CYP3A4 gene was detected. 
Because LIGHT associates with two receptors, LTR and HVEM, the expression 
of these receptors was also investigated in the hepatocytes. The specific PCR 
products of both receptor genes were detected by reverse transcriptase-PCR (Fig. 
2A) and the expression of both receptor proteins on the cell surface was 
determined by FACS analysis using LTR- and HVEM-specific antibodies (Fig. 2B 
and 2C). Therefore, the hepatocytes used in our experiments were confirmed to be 
physiologically normal and capable of responding to LIGHT through LTR and/or 
HVEM.  
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LIGHT has no apoptotic effect on human primary hepatocytes 
Several ligands of the TNF superfamily are able to induce apoptosis in 
some types of cells. To investigate whether LIGHT has cytotoxic effects on human 
primary hepatocytes, I examined LDH activity in culture supernatants 18 h after 
administration of LIGHT, TNF, LT, and Fas. As shown in Fig. 3, the level of 
LDH activity did not increase in response to any of these cytokines at 
concentrations ranging from 0.3 to 100 ng/ml. Pretreatment with transcriptional 
inhibitors like ActD has been reported to be required for TNF to cause apoptosis 
in cells such as murine hepatocytes (Beg et al., 1996; Wang et al., 1996; Van 
Antwerp et al., 1996; Matsushima et al., 2001). Therefore, the apoptotic effect of 
cytokines was examined in the presence of ActD. LDH activity increased when 
TNF and Fas were added in the presence of ActD. However, the LDH level did 
not increase 18 h after LIGHT treatment even in the presence of ActD. LT 
treatment did not show an obvious increase in LDH levels. Furthermore, the 
viability of cells was not reduced over a period of 18 h after LIGHT treatment 
(data not shown). LIGHT engages two known cellular receptors, LTR and HVEM, 
neither of which contain the so-called cytoplasmic death domain. However, death 
ligands, such as TNF and Fas ligand (FasL) engage receptors containing a death 
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domain in each cytoplasmic region; TNFRp55 and CD95, respectively. The lack of 
a death domain in both LTR and HVEM may be a possible reason that LIGHT 
did not cause apoptosis in hepatocytes. 
To investigate the type of cell death induced by these cytokines, 
hepatocytes were stained with annexin-V that recognizes phosphatidylserine on 
outer plasma membrane caused by apoptosis induction or propidium iodide that 
stains nuclear DNA in plasma membrane-damaged cells by apoptosis in the above 
conditions, and then they were analyzed by FACS. As shown in Fig. 4, the 
intensity of annexin-V and propidium iodide staining in ActD-treated cells was 
the same as that of autofluorescence suggesting that ActD could not cause 
apoptosis in human primary hepatocytes. The annexin-V staining patterns in 
hepatocytes treated with ActD alone were the same as those in hepatocytes 
treated with ActD plus LIGHT. In contrast, hepatocytes treated with ActD plus 
the other TNF family ligands such as TNF, LT, and Fas showed higher levels 
of annexin-V staining than those seen in hepatocytes treated with ActD alone. 
Propidium iodide staining also yielded similar results to those seen with 
annexin-V staining (Fig. 4). These results demonstrate that LIGHT does not 
induce apoptosis in human primary hepatocytes even in the presence of ActD, 
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whereas the other TNF family ligands induce apoptosis in hepatocytes pretreated 
with ActD. This indicates a functional difference between LIGHT and the other 
TNF family ligands. 
 
LIGHT pretreatment prevents human primary hepatocytes from undergoing 
ActD/TNF-induced apoptosis but does not prevent ActD/Fas- or 
ActD/TRAIL-induced apoptosis 
TNF has recently been reported to induce expression of not only the 
death factor(s) but also a putative survival factor(s) via NFB activation. Both 
LTR and HVEM are linked to an NFB activation pathway. To investigate 
whether LIGHT has an inhibitory effect on the hepatocyte apoptosis induced by 
other TNF family ligands, I examined effects of LIGHT pretreatment on 
ActD/TNF-, ActD/Fas-, and ActD/TRAIL-induced apoptosis. LDH release from 
hepatocytes was increased in a dose-dependent manner by the addition of TNF, 
TRAIL, and Fas in the presence of ActD. However, the LDH released 18 h after 
ActD/TNF administration was effectively blocked by LIGHT pretreatment (100 
ng/ml, 7 h) prior to ActD treatment. This indicates that LIGHT allowed the 
hepatocytes to avoid the apoptosis induced by ActD/TNF administration. 
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However, this pretreatment did not prevent hepatocyte apoptosis induced by 
ActD/Fas or ActD/TRAIL (Fig. 5). Therefore, LIGHT has an anti-apoptotic effect 
on ActD/TNF-treated hepatocytes but not on ActD/Fas- or ActD/TRAIL-treated 
cells. 
I subsequently examined the time point at which LIGHT administration 
has an inhibitory effect on ActD/TNF-induced apoptosis. As shown in Fig. 6, 
LIGHT pretreatment 1 h prior to ActD administration did not decrease the 
release of LDH compared with that of the control. However, initiating LIGHT 
treatment > 3 h prior to ActD administration decreased the LDH levels in 
hepatocytes. Therefore, pretreatment with LIGHT was required at least 3 h prior 
to ActD administration for an adequate anti-apoptotic effect.  
 
LIGHT induces NFB activation in human primary hepatocytes 
Our previous study demonstrated that LIGHT induces NFB activation of 
the human rhabdomyosarcoma cell line RD through either LTR or HVEM signal 
transduction (Hikichi et al., 2001). I investigated effects of LIGHT on NFB 
activation in human primary hepatocytes using an NFB-mediated SEAP 
reporter expression system (Clontech). SEAP activity in the hepatocyte culture 
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supernatants increased within 8 h of exposure to LIGHT, as shown in Fig. 7. This 
increase continued for 24 h (data not shown). TNF treatment resulted in a more 
rapid induction of SEAP levels than treatment with LIGHT, but Fas treatment 
did not result in induction. These results clearly indicate that LIGHT induced 
NFB in human primary hepatocytes like TNF.  
 
LIGHT inhibits caspase-3 activation in ActD/TNF-treated hepatocytes but not in 
ActD/Fas-treated hepatocytes 
Several caspases play important roles in TNF- and FasL-mediated 
apoptosis. To evaluate anti-apoptotic effects of LIGHT on hepatocytes, caspase-3 
processing was investigated using western blot analysis in cell lysates of 
ActD/TNF-treated hepatocytes with or without LIGHT pretreatment. Four 
hours after the initiation of ActD/TNF treatment, the cleavage product of 
caspase-3, p20, was clearly detected; thus, indicating that caspase-3 activation 
had occurred by that time (Fig. 8). Furthermore, 14 h after the initiation of 
ActD/TNF treatment, a decrease in the procaspase-3 level and the appearance of 
another cleavage product, p17, along with p20, were observed in the 
ActD/TNF-treated cells. The level of processed product, p20, observed in the cell 
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extract 14 h after the initiation of ActD/TNF treatment was not greater than the 
level observed at 4 h. Because both processed forms were further processed in 
their own proteolytic pathway, they might be highly unstable. In the presence of 
LIGHT, however, more procaspase-3 remained compared with that of the 
non-pretreated control, and p20 was absent 4 h after the initiation of ActD/TNF 
treatment (Fig. 8). Both cleavage products of caspase-3 were observed (as was the 
case in the non-pretreated control) even in the presence of LIGHT for 14 h after 
the initiation of ActD/TNF treatment, whereas the amount of pro-caspase-3 
observed in the sample that received pretreatment was much higher than the 
sample that did not receive pretreatment. On the other hand, there was 
considerably lower caspase-3 processing in the ActD/Fas-treated cells than in the 
ActD/TNF-treated cells at 4 and 14 h. There was no difference in the amount of 
the cleavage products observed in the reactions with and without LIGHT 
pretreatment (Fig. 8). I could not clearly detect a decrease in either procaspase-8 
or its cleavage products because of the nonspecific binding of the anticaspase-8 
antibodies (data not shown). These findings indicate that LIGHT effectively 
inhibits ActD/TNF-mediated caspase-3 activation but not Fas-mediated caspase 
activation.  
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Discussion 
 
 
LIGHT belongs to the TNF ligand superfamily and is known to have 
several physiological effects. These include the induction of apoptosis in certain 
tumor cell lines (Harrop et al., 1998; Zhai et al., 1998; Rooney et al., 2000), growth 
arrest in RD cells (Hikichi et al., 2001), and a costimulatory function of 
CD8-positive T cells (Tamada et al., 2000) in a manner similar to those reported 
for TNFand LT. Recent studies of LIGHT transgenic mice have revealed that 
constitutive expression of LIGHT causes loss of tolerance to autologous tissues; 
thus, leading to autoimmune syndromes (Wang et al., 2001; Shaikh et al., 2001). 
Although there are several studies regarding the physiological activities of LIGHT 
on the immune system and against tumors, little is known about its effects on 
normal hepatocytes. 
TNF has distinct physiological effects on hepatocytes. It causes either 
cellular proliferation during liver regeneration (Watanabe et al., 1997; Kirillova et 
al., 1999; Yamada et al., 1997; Webber et al., 1998) or apoptosis in ActD-sensitized 
cells (Leist et al., 1994). The physiological effect of TNF on hepatocytes is 
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dependent on the condition of the hepatocytes. In this part, I have shown that 
LIGHT did not induce apoptosis in ActD-sensitized hepatocytes, whereas TNF, 
LT, and Fas effectively induced apoptosis. These results were obtained even 
though both LTR and HVEM proteins, the specific receptors of LIGHT, were 
expressed on the hepatocytes (Fig. 2). In addition, LIGHT induced NFB 
activation in the hepatocytes (Fig. 7). I also revealed that LIGHT mRNA was 
predominantly expressed in both human adult and embryonic liver; it functioned 
as a sort of priming factor for the proliferation of hepatocytes, and it stimulated 
the production of several chemokines in the hepatocytes, including liver activation 
regulated chemokine (LARC) (data not shown). Thus, the results clearly 
demonstrate that LIGHT can stimulate some specific signal transductions 
through LTR and/or HVEM in human primary hepatocytes, although it is not 
able to induce the apoptosis of hepatocytes even in the presence of ActD. 
TNFRp55, an essential receptor for TNF signaling, stimulates TRAF dependent 
NFB activation. It also induces apoptotic signals leading to activation of the 
caspase proteolytic cascade via its downstream signal molecule TRADD (Liu et al., 
1996). Both cytoplasmic domains of LTR and HVEM proteins are known to 
associate with some TRAF family proteins and stimulate NFB activation 
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(Marsters et al., 1997; Hau et al., 1997; Nakano et al., 1996; Mackay et al., 1996; 
VanArsdale 1997). I had speculated that the TRAF-mediated signaling of both 
LTR and HVEM may be similar to that of TNFRp55 because the apoptosis 
induced by TNF in human primary hepatocytes requires transcriptional 
inhibition by RNA synthesis inhibitors like ActD. In addition, NFB activation is 
critical for the induction of resistance to TNFcytotoxicity (Liu et al., 1996; Beg et 
al., 1996; Wang et al., 1996; Van Antwerp et al., 1996).  
In part 1 of the present study, I attempted to determine whether LTR and 
HVEM possess a so-called death domain. I found that LIGHT prevented 
ActD-sensitized hepatocytes from TNF-mediated apoptosis, but it was not 
effective against Fas- and TRAIL-mediated apoptosis (Fig. 5). For an adequate 
anti-apoptotic effect, pretreatment with LIGHT was required for at least 3 h prior 
to ActD sensitization (Fig. 6); thus, indicating that the time period for expressing 
or activating an anti-apoptotic factor(s) may be essential for the maximal effect. 
Because TNF alone is not able to induce cell death in hepatocytes, it may 
simultaneously stimulate both a death signal(s) and a survival pathway(s) in the 
cells. There are some differences between the survival signal of LIGHT and of 
TNFwith regard to NFB activation. In the present study, NFB activation 
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mediated by LIGHT in hepatocytes was found to be less than that mediated by 
TNF (Fig. 7). Matsushima et al. (2001) recently reported that NFB-inducing 
kinase and inhibitor of B kinase- (IKK), but not TNFRp55, are essential for 
the induction of NFB through LTR. This suggests that LTR and TNFRp55 
stimulate NFB activation through distinct signal transduction pathways. 
Alternatively, the requirement for LIGHT pretreatment to observe the 
anti-apoptotic effect may be because of transcriptional inhibition by ActD. In any 
case, it remains to be determined whether the anti-apoptotic signals through 
LTR are the same as those through TNFRp55. This question may be answered 
through the observation of how hepatocytes that have the mutant TNFRp55 
lacking the ability to associate with TRAF proteins respond to TNF and LIGHT 
administration in the presence of ActD. It was shown that LTR and HVEM are 
constitutively expressed in hepatocytes (Fig. 2). HVEM is known to associate with 
TRAF1, 2, and 5, but not with TRAF6 (Marsters et al., 1997; Hau et al., 1997), 
whereas LTR associates with TRAF2, 3, and 5 (Nakano et al., 1996; Mackay et 
al., 1996; VanArsdale et al., 1997). TRAF2 and 5 have been shown to play a key 
role in modulating NFB activation in non-hepatic cells. In normal hepatocytes, 
however, I still have not identified the dominant receptor required for 
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LIGHT-mediated anti-apoptotic effects or its downstream TRAF molecules. 
Further studies are needed to address these issues.  
It is well known that TNF or Fas induce apoptosis by activating the 
proteolytic functions of caspases. I investigated caspase-3 processing during 
ActD/TNF- and ActD/Fas-induced apoptosis, with and without LIGHT 
pretreatment using western blot analysis (Fig. 8). One of the processed forms of 
caspase-3, p20, was detected in an extract four hours after TNF administration 
from ActD/TNF-treated cells but not in an extract from LIGHT-pretreated cells. 
Fourteen hours after the induction, however, I observed two processed forms of 
caspase-3, p20 and p17, and the amount of pro-caspase-3 dramatically decreased 
in the ActD/TNF-treated cells. There was a much smaller decrease in the 
amount of procaspase-3 in the LIGHT-pretreated cells. These findings indicate 
that caspase-3 activation is inhibited by LIGHT pretreatment during 
hepatocellular apoptosis, and this protective activity is effective at a minimum of 
4 h but is weaker at 14 h after the induction of apoptosis. Such a short-term effect 
of LIGHT may result from a decrease or inactivation of LIGHT-induced 
anti-apoptotic factor(s) by protein synthesis inhibition caused by ActD-mediated 
transcriptional inhibition. Although LIGHT did not rescue hepatocytes from 
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ActD/Fas- and ActD/TRAIL-induced apoptosis (Fig. 5), caspase-3 was found to be 
processed even in ActD/Fas-mediated apoptosis. The processing of caspase-3 
occurred later and was weaker than that in ActD/TNF-mediated apoptosis (Fig. 
8). It has recently been reported that caspase-3 inhibitors can protect hepatocytes 
from apoptosis in a galactosamine (GalN)/LPS-mediated liver injury model but 
not in a concanavalin A-mediated model (Kunstle et al. 1999). Because GalN was 
used as a transcriptional inhibitor for hepatocytes in the same manner as ActD 
and concanavalin A is known to induce FasL in several types of cells (including T 
cells), it may be that the cell death in GalN/LPS-treated mice is similar to that 
seen in the ActD/TNF-mediated process and that apoptosis in concanavalin 
A-treated mice is caused by FasL. Caspase-3 activation was not shown to be a 
critical step for hepatocellular cell death in a concanavalin A-mediated model 
even though caspase-3 is an important mediator of Fas in lymphocyte apoptosis 
(Enari et al., 1996). Furthermore, it has been reported that TNF prevents 
hepatocyte apoptosis in GalN/TNF-treated mice but not in Fas-treated mice 
(Nagaki et al. 2000). These data are consistent with my results.  
LIGHT can induce apoptosis in cell lines such as Hep3BT2, MDA-MB-231, 
WiDr, and HT-29 in the presence of IFN (van Eyndhoven et al., 1999; Harrop et 
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al., 1998; Zhai et al., 1998; Chen et al., 2000). These cells, including the primary 
hepatocytes, express LTR and HVEM. LTR affects apoptosis in HT-29 cells by 
interacting with TRAF3 (VanArsdale et al., 1997), HVEM binds TRAF2 and 5, 
which do not induce apoptosis but activate the NFB and JNK/AP-1 pathways 
(Marsters et al., 1997; Hau et al., 1997). To investigate the effect of LIGHT on 
IFN-sensitized hepatocytes, DNA synthesis in primary hepatocytes caused by 
treatment with LIGHT plus IFN was assessed using a bromodeoxyuridine 
incorporation assay. Although DNA synthesis was shown to be inhibited by IFN, 
LIGHT did not induce apoptosis in IFNsensitized hepatocytes (data not shown). 
The reason why these primary hepatocytes are resistant to IFN/LIGHT-mediated 
apoptosis is unknown. It may be that LIGHT induces several distinct signaling 
pathways depending on the condition of the cells. The present study is the first to 
show (using TNF family receptors lacking a death domain) that cellular signals 
can protect cells against apoptotic signals from receptors possessing a death 
domain. Further studies are needed to identify the anti-apoptotic factor(s) 
activated and/or induced by LIGHT in hepatocytes. Studies using a 
GalN/LPS-induced liver injury model should be conducted to investigate the 
suitability of LIGHT for clinical trials. 
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Figures 
 
Figure 2. Characterization of the human primary hepatocytes in this experiment  
A, Total RNA was prepared from human primary hepatocytes and analyzed by 
reverse transcriptase-PCR using CYP3A4-, LTR-, and HVEM-specific primers 
based on sequences of each gene. To check whether specific PCR occurred, PCR 
without the reverse transcriptase (RT) process (-RT) was carried out as a control. 
B, LTR; and C, HVEM proteins on the cell surface of human primary hepatocytes 
were determined by FACS analysis. Human primary hepatocytes were stained 
with specific antibodies against LTR and HVEM, following FITC-conjugated 
secondary antibodies, and each receptor expression level was determined by FACS 
analysis (—). Cells treated solely with second antibodies were used as an 
unstained negative control (- - -). 
 
 
 
 
 
45 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2 
 
 
 
 
RT -RT
M L
T
β
R
C
Y
P
3
A
4
L
T
β
R
C
Y
P
3
A
4
+RT
M L
T
β
R
H
V
E
M
C
Y
P
3
A
4
L
T
β
R
H
V
E
M
C
Y
P
3
A
4
M L
T
β
R
C
Y
P
3
A
4
L
T
β
R
C
Y
P
3
A
4
 RT RT
M L
T
β
R
H
V
E
M
C
Y
P
3
A
4
L
T
β
R
H
V
E
M
C
Y
P
3
A
4
HUVEM
LTβR
HVEM
A B
C
46 
 
 
 
Figure 3. TNF, LT, and Fas, but not LIGHT, increase LDH release in the 
presence of ActD. 
Human primary hepatocytes were incubated in basal medium in the presence of 
various concentrations of LIGHT, TNF, LT, or Fas with or without 333 nM 
ActD for 18 h. The cytotoxicity of each well was determined by measuring LDH 
release. Data are expressed as mean ± S.E., n = 3. 
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Figure 4. TNF, LT, and Fas, but not LIGHT, induce apoptosis in 
ActD-sensitized hepatocytes.  
Human primary hepatocytes, treated as described in experimental procedures, 
were stained with FITC-conjugated annexin-V or propidium iodide, and were 
analyzed by FACS analysis. 
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Figure 5. LIGHT protects hepatocytes from ActD/TNF-mediated cell death, but 
not from that caused by ActD/Fas or ActD/TRAIL. 
Human primary hepatocytes were pretreated with or without 100 ng/ml LIGHT at 
7 h before ActD administration combined with various concentrations of TNF, 
Fas, or TRAIL, and were further treated as described in the legend to Fig. 3. 
Data are expressed as mean ± S.E., n = 3. 
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Figure 6. The LIGHT-mediated anti-apoptotic effect requires LIGHT 
pretreatment at least 3 h prior to ActD administration in hepatocytes.  
Human primary hepatocytes were treated with 100 ng/ml LIGHT at different 
times as indicated before ActD administration, followed by treatment as described 
in the legend to Fig. 5. Data are expressed as mean ± S.E., n = 3. 
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Figure 7. LIGHT induces NFB activation in human primary hepatocytes.  
Human primary hepatocytes transfected with NFB dependent SEAP expression 
plasmids were stimulated with LIGHT, TNF, or Fas. Culture supernatants 
were collected at each of the indicated time points, and NFB activation was 
determined by measuring the SEAP activities. SEAP activities were expressed in 
chemiluminescent signal (CFU) detected on a plate luminometer, and the results 
are plotted as mean ± S.E., n = 4. 
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Figure 8. LIGHT attenuates TNF-mediated caspase-3 processing, but not that 
by Fas.  
Cell extracts from untreated, ActD/TNF-, or ActD/Fas-treated hepatocytes 
pretreated with or without LIGHT were obtained at 4 and 14 h after ActD 
administration, and were determined by western blotting with anti-caspase-3 
antibodies. The presence of pro-caspase-3, p20, and p17 are indicated by arrows. 
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Part 2 
Expression of ICAM-1 on Glomeruli is Associated with Progression of Diabetic 
Nephropathy in a Genetically Obese Diabetic Rat, Wistar Fatty 
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Abstract 
 
 
To elucidate the relationship between TNF and non-inflammatory 
disease (diabetic nephropathy), I focused on ICAM-1 expression as a marker for 
TNF expression in tissues of interest. First, a genetically obese rat strain known 
as Wistar fatty was developed as an animal model of non-insulin-dependent 
diabetes mellitus. These rats show obesity-related features such as 
hyperinsulinemia and hyperlipemia. However only males develop diabetic 
features, including hyperglycemia, glucoseuria and polyuria, as they age. 
Histopathological study revealed a deposition of PAS-positive granules in 
epithelial cells, a diffuse thickening of the mesangial area, and moderate changes 
in the renal tubules. I found that ICAM-1 is expressed on the glomeruli of male 
Wistar fatty rats and that its expression is associated with the development of 
nephropathy. ICAM-1 expression is weak at 5 weeks, becomes markedly strong at 
15 weeks, and progresses further at 29 weeks of age. I administered monoclonal 
anti-ICAM-1 in vivo (alone or in combination with anti-LFA-1) to male Wistar 
fatty rats during the period from 5 weeks to 17 weeks of age. The treatment, 
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however, could not prevent the development of nephropathy. ICAM-1 expressed on 
the glomeruli of Wistar fatty rats does not seem to play a key role in the 
development of nephropathy by mediating leukocyte infiltration; however it will 
be a useful marker for the development of the disease. 
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Introduction 
 
 
As described in part 1, the complexity of TNF signaling enabled me to 
speculate about the existence of physiological roles for TNF that are distinct 
from apoptosis and inflammatory reactions. It has been reported that regulation 
of expression of adhesion molecules is one of the inflammatory reaction by TNF. 
Over 20 years ago, it was difficult to detect the amount of TNF in specific tissues 
of interest, but the expression of adhesion molecules may be utilized as a 
surrogate marker for TNF expression in those tissues. 
 Intercellular adhesion molecule-1 (ICAM-1), a 90-kDa adhesion molecule 
encoded by a member of an immunoglobulin supergene family, is a cell-surface 
ligand of integrins, lymphocyte function-associated antigen-1 (LFA-1), and Mac-1. 
ICAM-1 is known to play important roles in various cell-cell interactions in the 
immune system (Dustin et al., 1988; Wawryk et al., 1989). It is involved in the 
leukocyte-endothelial cell interaction, which controls the extravasation of 
leukocytes into connective tissues, particularly in inflammatory reactions. Recent 
studies have found that ICAM-1 is expressed in renal tissue in some human renal 
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diseases, including focal segmental glomerulosclerosis, rapidly progressive 
glomerulonephritis, and lupus nephritis (Chow et al, 1992; Lhotta et al, 1991; 
Canton et al, 1992). In vivo administration of anti-ICAM-1 antibody to model 
animals with renal dysfunction (in which infiltration of inflammatory cells are 
observed) demonstrated that ICAM-1 plays a key role in the pathogenesis of these 
diseases (Kawasaki et al., 1993; Nishikawa et al., 1993; Kelly et al., 1994; 
Harning et al., 1992). However, it is not known whether ICAM-1 is involved in the 
pathophysiology of renal diseases in which infiltration of the cells is considered 
unimportant, although the expression of ICAM-1 was reported to be increased in 
rat mesangial cells by TNF (Brennan et al., 1990; Sterzel et al., 1993). Diabetic 
nephropathy is one of the renal diseases that proceed without infiltration of 
inflammatory cells into glomeruli. Pathological features of this disease are 
glomerulosclerosis, arteriosclerosis, and morphological changes of the glomerulus 
such as capillary basement membrane thickening, diffuse glomerulosclerosis, and 
nodular glomerulosclerosis (Cotran et al., 1989). The mechanisms of progression 
to diabetic nephropathy are not well understood. Therefore, it is important to 
establish an in vivo diabetic animal model to develop our understanding of the 
disease. 
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A genetically obese hyperglycemic rat strain, the Wistar fatty rat strain, 
was previously developed as a model for non-insulin-dependent diabetes mellitus 
(Ikeda et al., 1981). This strain was established by transferring the 
obesity-induced gene fa from the heterozygous Zucker rat to the Wistar Kyoto rat 
with blunted insulin sensitivity. Wistar fatty rats show obesity-related features 
such as hyperinsulinemia and hyperlipemia. Only males show diabetic features, 
including hyperglycemia, glucoseuria, and polyuria. Furthermore, Wistar fatty 
males develop diabetic nephropathy (Diani et al., 1988).  
In the part 2, I studied the expression of ICAM-1 in the kidney section 
from Wistar fatty rats by immunostaining using a monoclonal antibody against 
rat ICAM-1 (1A29; Tamatani et al., 1990). I also examined the participation of 
ICAM-1 in the development of nephropathy by in vivo administration of 
anti-ICAM-1. 
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Materials and Methods 
 
 
Animals 
Wistar fatty rats and Wistar lean rats were bred by Takeda 
Pharmaceutical Company Ltd., and allowed free access to food and water. 
 
Analytical methods 
Blood samples were taken from the tail vein under the fed condition at 
08:30-09:30 h. Plasma glucose was determined by a glucose-oxidase assay kit 
using glucokinase (Iatron, Tokyo, Japan). Plasma triglyceride was determined by 
an enzymological assay kit using L--glycerophosphate oxidase (Iatron). Plasma 
cholesterol was determined by an enzymological assay kit using 
cholesterol-esterase and cholesterol-oxidase (Iatron), urinary samples (16 h) were 
collected in metabolic cages and their volumes were measured. Urinary protein 
excretion was measured by the Lowry method (Lowry et al., 1951). Urinary 
albumin was measured by an immunological method (Mohamed et al., 1984). 
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Antibodies 
A mouse IgG1 monoclonal antibody against rat ICAM-1 (1A29) and a 
mouse IgG2a monoclonal antibody against rat LFA-1 (WT.1) were generated and 
characterized as previously described (Tamatani et al., 1990; 1991). A mouse 
monoclonal antibody against human CR1 (57H, IgG1) was used as an 
isotype-matched control. Biotinylated F(ab)'2 fragment of anti-mouse IgG was 
purchased from Amersham Laboratories Inc. (Buckinghamshire, UK). 
Fluorescein-conjugated (FITC) streptavidin was purchased from vector Labs Inc. 
(Burlingame, USA). Goat antibodies against rat Ig and rat C3 and FITC 
conjugated rabbit anti-goat Ig (H +L) were purchased from Cappel Laboratories 
(Durham, USA). 
 
Histology 
After Wistar fatty and lean rats (six per group) at 17 weeks of age were 
sacrificed, the kidneys were removed, and fixed in 10% buffered formalin. The 
tissues were embedded in paraffin, 4 m thick sections were taken and stained 
with hematoxylin and eosin, periodic acid-Schiff (PAS) reagent and periodic 
acid-methenamine-silver (PAM). The sections were examined on light microscopy. 
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Immunohistochemical methods 
Ten m frozen sections were fixed in cold methanol for 10 min. After 
washing with PBS, the sections were incubated with PBS containing 2% bovine 
serum albumin (BSA, Fraction V; Wako Chem.Inc., Osaka, Japan) for 1 h at room 
temperature. They were washed three times with PBS containing 0.1% BSA and 
then treated with endogenous avidin biotin blocking kit (Nichirei Inc., Tokyo, 
Japan) followed by a wash. They were incubated either with 1A29 or 57H ascites 
at a dilution of 1:500 overnight at 4°C. After washing, they were incubated with 
F(ab)'2 fragment of biotin-labeled anti-mouse IgG (1.7 g/ml) for 1 h. They were 
washed and further incubated with FITC-streptavidin (25 g/ ml) for 1 h at room 
temperature. Finally, the sections were mounted in glycerol-PBS solution 
(glycerol/PBS, 9:1) containing p-phenylenediamine to reduce fading (Platt et al., 
1983) and examined with an Olympus microscope equipped with epifluorescence 
optics and appropriate filters. Pictures were taken of glomeruli, which showed a 
typical staining among several sections. Almost all glomeruli in one section 
showed similar degree of staining. The strength of ICAM-1 expression was 
classified as follows: ±, weak; +, moderate; ++, strong. In some experiments 
where specified, I used FITC-conjugated rabbit anti-mouse Ig (1:100) instead of 
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biotinylated F(ab)'2 fragment of anti-mouse IgG to avoid the non-specific reaction 
to avidin. 
 
Administration of anti-ICAM-1 and anti-LFA-1 antibodies to Wistar fatty rats  
Twenty Wistar fatty rats at 5 weeks of age were divided into four groups of 
five rats and treated either with PBS, anti-ICAM-1 (1A29), anti-LFA-1 (WT.1) or 
with both antibodies. Wistar lean rats (n=5) were treated with PBS as negative 
control. 1A29 and WT.1 were given intraperitoneously at a dose of 3 mg/kg twice a 
week during the period from 5 to 17 weeks of age. Urinary albumin excretion was 
measured at 6, 9, 12, 14, 16 and 18 weeks of age, and the immunostaining was 
performed at 19 weeks of age. 
 
Statistical analysis 
Data are expressed as mean ± S.D. Differences of means between fatty rat 
groups and lean rat groups were statistically analysed by two-way ANOVA with 
Bonferroni's multiple comparison test.  
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Results 
 
 
Development of diabetic nephropathy in Wistar fatty rats 
The plasma glucose levels in Wistar fatty rats increased with age. They 
were 160 mg/dl at 6 weeks and 350 mg/dl at 17 weeks of age. In contrast, the 
plasma glucose levels in Wistar lean rats remained below 150 mg/dl throughout 
the observation period. The plasma triglyceride levels of Wistar fatty rats were 
120 mg/dl, a significantly higher level than that seen in Wistar lean rats, 40 mg/dl 
at 6 weeks of age. Triglyceride levels reached 400 mg/dl at 18 weeks of age, 
whereas those of Wistar lean rats showed a slight increase to approximately 100 
mg/dl. The difference in plasma cholesterol levels between Wistar fatty and 
Wistar lean rats became apparent at 12 weeks of age. The plasma cholesterol 
levels of Wistar fatty and Wistar lean rats at 18 weeks of age were 160 mg/dl and 
90 mg/dl, respectively (Fig. 9).  
I measured the daily urinary excretion of proteins and albumin to analyze 
the development of renal dysfunction. Urinary protein levels were low in both 
types of rat until 9 weeks of age. After 12 weeks of age, however, the urinary 
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protein levels of Wistar fatty rats started to increase, reaching 140 mg/day at 18 
weeks, whereas the levels in Wistar lean rats remained low: 40 mg/day at 18 
weeks of age. Excretion of large molecular weight proteins into urine was 
determined by measuring urinary albumin. Wistar fatty rats excreted a 
significant amount of albumin into their urine at 9 weeks of age, and its level 
reached 45 mg/day at 18 weeks of age. In contrast, Wistar lean rats did not excrete 
a detectable amount of albumin throughout the observation period (Fig. 10). 
 
Histopathological finding of the kidney 
The renal glomeruli of Wistar fatty rats showed a mild to moderate 
deposition of PAS-positive granules in the epithelial cells and a diffuse thickening 
of the mesangial area (Fig. 11A). In the renal tubules, mild and moderate changes 
were observed, including glycogen vacuolization, basophilia, thickening of 
basement membrane, hyaline cast formation, microcalcification, dilatation, and 
appearance of eosinophilic bodies in the epithelial cells. In Wistar lean rats, 
however, no changes were observed in renal glomeruli and tubules (Fig. 11B). 
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Expression of ICAM-1 in the kidneys of Wistar fatty rats 
I examined the expression of ICAM-1 in renal tissues of Wistar fatty rats 
and Wistar lean rats using immunohistochemical staining. As shown in Fig. 12, a 
diffuse, segmental, and strong staining of ICAM-1 was observed in the glomeruli 
of Wistar fatty rats, whereas only a faint staining was observed in Wistar lean 
rats at 17 weeks of age. I further studied the age-dependent expression of ICAM-1 
from 5 to 29 weeks in the glomeruli of Wistar fatty and lean rats (Table 1). In both 
types of rat, ICAM-1 was weakly expressed at 5 weeks of age. After 15 weeks of 
age, however, expression of ICAM-1 became markedly stronger and diffused in 
Wistar fatty rats. The increase progressed further as they aged, whereas it 
remained weak in Wistar lean rats. I repeated the staining experiments at least 
three times and obtained similar results; thus, showing a marked increase of 
ICAM-1 staining in the glomeruli of Wistar fatty rats after 15 weeks of age. The 
elevated level of ICAM-1 expression in the glomeruli is associated with, or 
followed by, the increased excretion of urinary proteins. Because I could not 
demonstrated the specificity of the ICAM-1 staining in the renal tubules due to a 
non-specific staining with avidin, which is known to cross-react with kidney 
sections, I stained these tissues with FITC-conjugated rabbit anti-mouse Ig. 
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Specific expression of ICAM-1 was observed at the basement membrane and 
interstitium of the renal tubules, but not in the renal epithelial cells, in Wistar 
fatty and lean rats. Thus, the expression of ICAM-1 increased significantly with 
age only in glomeruli of Wistar fatty rats. 
 
In vivo administration of anti-ICAM-1 antibody 
I administered anti-ICAM-1 antibody (alone or in combination with 
anti-LFA-1 antibody) to Wistar fatty rats. Rats treated with antibodies showed 
albuminuria comparable to that seen in control rats (Fig. 13). These treatments 
did not appear to prevent Wistar fatty rats from developing nephropathy. At 19 
weeks of age, these rats were sacrificed and their kidney sections were examined. 
Frozen sections were stained with biotin-labeled anti-mouse IgG followed by 
FITC-streptavidin. Strong staining was observed in the glomeruli of the Wistar 
fatty rats administered with anti-ICAM-1 antibody; thus, showing that the 
antibodies had reached the glomeruli. Formalin-fixed sections were examined 
carefully for their histopathological features. I found no significant change in the 
sections of Wistar fatty rats regardless of the anti-ICAM-1 antibody treatment. A 
diffuse thickening of the mesangial area was observed in the glomeruli; hyaline 
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cast formation, dilatation, and basophilia were observed in the renal tubules of 
both groups of rats. Negative staining of the kidney section with anti-rat Ig and 
anti-rat C3 excluded the possibility that nephropathy developed in the 
antibody-treated rats due to the deposition of immune complexes. Thus, in vivo 
administration of anti-ICAM-1 antibodies failed to prevent the development of 
nephropathy in Wistar fatty rats. 
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Discussion 
 
 
I demonstrated that the level of ICAM-1 expression in the glomeruli of 
Wistar fatty rats increased in association with the development of diabetic 
nephropathy. Although I was not able to identify the cell type that showed a 
marked increase in the expression of ICAM-1, there are several lines of evidence 
suggesting that the mesangial cells are likely candidates. The mesangial region of 
diabetic Wistar fatty rats expands weakly and resembles the staining pattern 
with anti-ICAM-1. Primary cultured mesangial cells obtained from rat glomeruli 
showed an elevated expression of ICAM-1 upon stimulation with TNF or IL-1 
(Brennan et al., 1990; Sterzel et al., 1993).  
ICAM-1 is one of the adhesion molecules that play important roles in the 
infiltration of leukocytes into inflammatory regions. However, infiltration of 
leukocytes into the glomeruli of Wistar fatty rats was not observed where ICAM-1 
expression was highly elevated. I tried to administer anti-ICAM-1 antibody to 
Wistar fatty rats. Under the experimental conditions, there was no effect on the 
development of nephropathy. Strong staining by anti-mouse Ig antibody was 
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observed in the glomeruli of Wistar fatty rats treated with anti-ICAM-1 antibodies, 
which means the exposure of the antibodies in kidneys of the treated rats. 
Although anti-ICAM-1 antibodies reached the glomeruli of Wistar fatty rats, they 
did not prevent the development of nephropathy. Is the level of ICAM-1 expression 
related to the development of nephropathy? It has been shown that 
administration of anti-ICAM-1 antibody to rats with experimentally developed 
renal dysfunction associated with leukocyte invasion such as nephrotoxic serum 
nephritis and ischemic acute renal failure model rats prevents the development of 
proteinuria in these rats (Kawasaki et. al., 1993; Nishikawa et. al., 1993; Kelly et. 
al., 1994). With regard to no infiltration of leukocytes in kidney of Wistar fatty 
rats, it has been reported that T Lymphopenia was observed in Wistar fatty rats 
(Tanaka et al., 2000), suggesting that Wistar fatty rats might have some types of 
immune system deficits. These deficits could be one of causes in no infiltration of 
leukocytes in kidney of Wistar fatty rats, although the mechanism still remains 
unknown.  
The pathogenesis of the non-insulin-dependent diabetic nephropathy is 
not yet fully understood. In our animal model, male Wistar fatty rats show high 
plasma glucose levels, whereas females failed to show similar levels. In addition, 
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both males and females show similar profiles in other parameters such as plasma 
triglycerides. Only Wistar fatty males develop proteinuria; thus, suggesting that 
high plasma glucose may cause the development of proteinuria in Wistar fatty 
rats. It has been reported that rat mesangial cells cultured under high glucose 
conditions show upregulation of fibronectin expression (Nahman et al., 1992). In 
male Wistar fatty rats, strong staining with PAS was observed in the mesangial 
region; thus, indicating expansion of the extracellular matrix. 
The Wistar fatty rat was developed by transferring the fa gene from the 
Zucker fatty rat to the Wistar Kyoto rat (Ikeda et al., 1981). ICAM-1 expression 
was not observed in Wistar lean rats heterozygous for the fa gene (Fig. 12) or in 
female Wistar fatty rats who are homozygous for the fa gene but do not show 
diabetes (data not shown). These data excluded genetic background as the direct 
cause of the elevated expression of ICAM-1.  
In conclusion, I found that ICAM-1 expression was elevated in the 
glomeruli of Wistar fatty rats. The increase is associated with the progression of 
nephropathy. These finding suggest that ICAM-1 is a very useful marker for the 
diabetic nephropathy although it is unlikely to play a key role in the development 
of the nephropathy with no infiltration of immune cells. 
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Figures and a Table 
 
Figure 9. Change in plasma glucose, triglyceride and cholesterol in Wistar fatty 
rats. 
Plasma glucose (A), triglyceride (B) and cholesterol (C) in male Wistar fatty rats 
(black circle) and their lean littermates (white circle). mean ± S.D., n = 5.     
*p < 0.05, **p < 0.01, and *** p < 0.001 vs. the corresponding lean rats. 
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Figure 9 
 
 
 
 
78 
 
 
 
Figure 10. Change in urinary proteins and albumin in Wistar fatty rats. 
Urinary proteins (A) and albumin (B) in male Wistar fatty rats (black circle) and 
their lean littermates (white circle). mean ± S.D., n = 5. *p < 0.05, **p < 0.01, 
and *** p < 0.001 vs. the corresponding lean rats. 
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Figure 10 
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Figure 11. Staining with periodic acid-methenamine-silver of glomeruli from 
Wistar fatty rat 
Wistar fatty rat (A), lean rat (B) at 17 weeks of age. Bars, 5 m. 
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Figure 11 
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Figure 12. Immunostaining with anti-ICAM-1 antibody in glomeruli. 
Wistar fatty rat (A) and lean rat (B) at 17 weeks of age. Bars, 2.5 m. 
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Figure 12 
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Figure 13. Administration of anti-ICAM-1 and anti-LFA-1 antibodies to Wistar 
fatty rats. 
Wistar fatty rats were treated either with PBS (black circle), with 1A29 (triangle), 
with WT.1 (rectangle), or with 1A29 and WT.1 (diamond), and Wistar lean rats 
were treated with PBS (white circle). mean ± S.D., n = 5. 
 
 
 
 
 
 
 
 
 
 
 
85 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 13 
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Table 1. Age-dependent expression of ICAM-1 from 5 to 29 weeks in glomeruli of 
Wistar fatty and lean rats. 
 
 
 
 
 
 
Expression coded as follows; ±, weak; +, moderate; ++, strong. 
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General discussion 
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Members of the TNF superfamily have a large variety of physiological 
functions. This current study was designed not only to elucidate the mechanism 
that determine cell fate (survival or apoptosis) based on the resistance of several 
normal cells to TNF apoptosis, but also to discover physiological functions other 
than those previously identified in non-inflammatory diseases. First, the 
anti-apoptotic effect of LIGHT, which binds non-DD bearing receptors, was 
evaluated in ActD- and TNF-treated human normal hepatocytes (part 1). Second, 
ICAM-1 expression was evaluated in the kidney of Wistar fatty rats to investigate 
whether the expression of ICAM-1 could be utilized as a surrogate marker for 
TNF expression (part 2).    
In part 1, I first examined the apoptotic activity of several members of the 
TNF superfamily in human primary hepatocytes. LIGHT failed to induce 
apoptosis in ActD-sensitized hepatocytes, whereas TNF, LT, and Fas 
effectively induced the apoptosis, even though both LTR and HVEM (specific 
receptors of LIGHT) which possess no authentic DD were expressed on the 
hepatocytes. In addition, LIGHT induced NFB activation in the hepatocytes. 
These results suggest that LIGHT is able to activate an NFB pathway, but not 
an apoptotic signaling pathway. Moreover, as expected, I also discovered that 
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LIGHT prevented ActD-sensitized hepatocytes from TNF-mediated apoptosis. 
These results suggest that TNF-mediated apoptosis is suppressed by the 
signaling from TNF receptors lacking DDs. 
It seemed that these mechanisms could be an effective way to induce 
appropriate apoptosis along with changes of cell state and fate. I had no reason 
why LIGHT failed to rescue ActD/Fas- or TRAIL-treated cells from apoptosis in 
my studies. It was reported that TNF- but not Fas-related apoptosis required 
sensitization of hepatocytes in mice (Nagaki et al., 1999). Fas signaling may 
stimulate apoptotic pathways different from those stimulated during 
TNF-mediated apoptosis which were resistant to NFB activation. 
After my studies, a substantial amount of research on TNF signaling has 
been conducted. First, Tchikov et al. (2011) focused on the compartmentalization 
of TNFRp55 and CD95 pro- and anti-apoptotic signaling. Recent findings reveal a 
regulatory role for receptor internalization and intracellular trafficking in 
selectively transmitting signals that lead either to apoptosis or to the survival of 
the cell; thus, providing a clue to the understanding of these contradictory 
phenomena. Second, RIP and TRADD are competitively bound to TNFRp55 after 
exposure of TNF, which results in the switch between NFB activation and 
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caspase processing. Dominant recruitment of TRADD induced NFB activation 
whereas that of RIP did caspase activation. In the case of Fas and TRAIL 
receptors, the competitive binding was not identified. The difference might be 
one of the answers for the incompetent of NFB on Fas or TRAIL-mediated 
apoptosis. Third, NFB inhibition by an IKK mutant enhanced TNF- but not 
TRAIL-mediated apoptosis in a keratinocytes cell line by increasing the level of 
caspase-8 activation (Diessenbacher et al., 2008). Thus, several findings have 
revealed the mechanisms behind the anti-apoptotic effects of TNF, Fas and 
TRAIL signals could suppress this mechanism, which would result in their ability 
to induce apoptosis in LIGHT-pretreated cells. 
Differences between the NFB activation modalities of TNF and LIGHT 
were reported (Madge et al., 2010). It was revealed that TNF-induced classical 
NFB signaling upregulates RelB expression, which inhibits both the basal and 
non-canonical NFB-dependent CXCL12 expression induced by LIGHT. This 
means that TNF activates classical or canonical NFB, whereas LIGHT 
activates only non-canonical NFB. They also described several studies that 
indicated a role for p100 and RelB as positive regulators of the classical NFB 
activation pathway; thus, suggesting an interplay between the non-canonical and 
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classical pathways. Therefore, it has been validated that two distinct NFB 
pathways are activated by TNF and LIGHT, respectively, while TNF and 
LIGHT enable the prevention of apoptosis via NFB activation in my studies. 
Intracellular signaling via the TNF superfamily has been elucidated by 
numerous studies over the past 20 years. A range of results, summarized by 
Liedtke et al. (2012), have led to the identification of the role of the IKK family in 
TNF intracellular signaling, as well as the threshold model for the induction of 
apoptosis by enhanced caspase-8 gene expression. Caspase-8 activation by Fas 
inhibits NFB activation in Jurkat cells by the degradation of IKK/Nemo (Frelin 
et al., 2008). FADD inhibits NFB activation in cardiomyocytes (Chao et al., 2005). 
Contrary to the results described above, LTR signaling induced NFB activation 
but failed to protect HT29-derived carcinoma cells from apoptosis (Vanarsdale et 
al 1997). Induction of NFB by TNF and IL-1 has a pro-apoptotic role in 
pancreatic beta cells (Ortis et al. 2008). These types of findings suggest that the 
regulation of apoptosis by the TNF superfamily is dependent on cell type, other 
stimuli, and the environment surrounding the cells. 
 Apoptosis is thought to play important roles in the processes of 
organogenesis and differentiation. Disruption of the RelA gene, which is a 
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member of the NFB family, was reported to cause apoptosis of hepatocytes 
during ontogenesis. These cells can be rescued by crossbreeding of the mice with 
TNF KO mice (Doi et al., 1999). Furthermore, Anders et al. (2005) reported that 
marked hyperplasia of the liver was observed in LIGHT transgenic mice, whereas 
mice deficient in LTR signaling have a severe defect for survival from partial 
hepatectomy; thus, suggesting that the upregulation of NFB signals derived 
from TNF superfamily ligands plays a considerable role in hepatocyte survival 
and liver regeneration. 
In part 2, I tried to utilize ICAM-1 expression as a surrogate marker for 
TNF expression based on a previous study that TNF induced ICAM-1 
expression in mesangial cells (Brennan et al., 1990; Sterzel et al., 1993). Our 
findings revealed that ICAM-1 expression in the kidney of a genetically obese 
diabetic rat: Wistar fatty rats increased along with an increase in urinary 
proteins; thus, suggesting that ICAM-1 expression is correlated with the 
progression of nephropathy. To elucidate the effects of ICAM-1 on the incidence of 
diabetes symptoms, chronic administration of anti-ICAM-1 antibodies was 
performed in Wistar fatty rats. The treatment failed to reduce the elevation of 
urinary albumin in Wistar fatty rats; thus, suggesting that ICAM-1 has a limited 
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role in disease progression, although ICAM-1 may serve as a surrogate marker for 
TNF expression in the kidney during diabetic nephropathy. 
As unresolved questions, our findings failed to achieve notable results that 
would enable me to understand the implication of ICAM-1 or the relationship of 
TNF with diabetic nephropathy. These issues have been addressed by plenty of 
studies after my studies were completed. First, an increase in plasma TNF was 
confirmed in the Wistar fatty rats used in part 2 (Murase et al. 1998). In addition, 
ICAM-1 expression has been identified in other diabetic nephropathy models such 
as streptozotocin-treated animals, which has resulted in the growing acceptance 
of the generality of ICAM-1 expression in diabetic nephropathy (Watanabe et al., 
2011). On the other hand, infiltration of white blood cells was observed in the 
kidneys of other diabetic nephropathy models. This infiltration was suppressed by 
anti-ICAM-1 antibodies and in ICAM-1 knockout mice (Sugimoto et al., 1997; 
Miyatake et al., 1998; Okada et al., 2003; Chow et al., 2005). Therefore, a 
difference in filtration of immune cells between this model and the others was 
observed, whereas a similar ICAM-1 expression pattern was obtained among 
some diabetic models. The reason for this still remains unknown. However, a 
speculation was raised that it was due to the difference in genetic background 
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among them, considering that the Wistar fatty rat was generated by 
crossbreeding between Wistar Kyoto and Zucker fatty bearing fa gene, which 
might result in T Lymphopenia (Tanaka et al., 2000). 
Many findings on relationship of TNF and ICAM-1 with diabetic 
nephropathy have been described. It was reported that TNF synthesis and the 
concentration of TNF in the kidney of diabetic rats were correlated with urinary 
albumin, as well as with ICAM-1, as described above (Navarro et al., 2005; 2006). 
The soluble plasma ICAM-1 concentration was also correlated with urinary 
albumin in diabetic patients (Lenghel et al., 2012). Moreover, plasma and urinary 
TNF were correlated with urinary albumin in patients with type 2 diabetes (Lu 
et al., 2011; Wu et al., 2013). These results indicate a relationship between TNF 
and ICAM-1 associated with diabetic nephropathy. With respect to the mechanism 
of pathogenesis, Elmarakby et al. (2012) summarized a number of studies that 
TNF induced by oxidative stress during hyperglycemia upregulates ICAM-1 
expression. These findings and the studies presented in part 2 support the 
possibility that TNF could play meaningful roles in positive feedback systems of 
oxidative stress and in induction of pro-inflammatory factors like ICAM-1, which 
may result in the infiltration of immune cells into kidneys during diabetic 
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nephropathy. 
In conclusion, the findings described in part 1 reveal that TNF-mediated 
apoptosis is effectively suppressed by pretreatment with LIGHT; thus, suggesting 
that some TNF superfamily ligands can negatively regulate TNF-mediated 
apoptosis. As described in part 2, ICAM-1 expression, which is expected to serve 
as a surrogate marker for TNF expression, was increased in the glomeruli of 
kidney in Wistar fatty rats; thus, suggesting that the pro-inflammatory cytokine 
TNF has the potential to play pathophysiological roles in non-inflammatory 
diseases like diabetic nephropathy. These results obtained from my studies 
indicate a part of a wide variety of physiological implications for TNF superfamily. 
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